Skip to main content

Table 2 Comparison serum profiles time-course

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z p-value peptide ID
904.4726 0.00054514 BK
1129.4849 0.0013845 FPB
1183.5995 0.0094174  
1201.5663 0.0045301  
1263.5958 0.0024011 FPA
1288.6006 0.0013845  
1347.5297 0.047967  
1350.6275 0.0013845 FPA
1389.6433 0.0013845  
1402.671 0.0089624  
1418.539 0.026155  
1432.644 0.039554  
1440.5407 0.011867  
1445.5828 0.0032159  
1447.6855 0.005355  
1450.4893 0.024048  
1456.5093 0.039554  
1458.4946 0.020271  
1460.6257 0.0022586  
1477.6539 0.010181  
1479.6646 0.005355  
1487.6226 0.0017206  
1491.6634 0.0074232  
1501.748 0.011  
1503.5994 0.0087051  
1507.6643 0.0024697  
1536.6906 0.0087051 FPA
1552.669 0.003822 Glu-FBP
1561.7288 0.00048292  
1569.6823 0.0014303  
1573.7005 0.0022586  
1616.6366 0.013817 P-FPA
1630.6679 0.0022586  
1670.5947 0.011876  
1690.9254 0.03325 C3f
1777.966 0.0087051 C3f
1865.0022 0.011 C3f
2494.1536 0.030814  
2567.3659 0.00032806 seAlb
2602.3048 0.019183 CF XIIIA
2743.4663 0.005355  
2747.4349 0.0014303  
2789.0914 0.037043  
3156.6207 0.020803 ITIH4
  1. In NSCLC patients, 44 peaks were significantly differential over the three time points: pre-treatment, after two cycles of treatment and end of treatment. Ordered by m/z value. Abbreviations: BK: bradykinin; FBP: fibrinopeptide B; FPA: fibrinopeptide A; Glu-FPB: Glu-1-fibrinopeptide B; P-FPA: phospho-fibrinopeptide A; C3f: complement C3 f; seAlb: serum albumen; CFXIIIA: coagulation factor XIIIA; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4.